Hot Features
プレミアム
CervoMed Inc (CRVO)
NASDAQ
BLACK FRIDAY
25周年を記念 1999-2024
Forexで最大60%オフ
1年間40％、2年間40％、*3年間60％
リアルタイム株価 | レベル2 | |
|---|---|---|
Forex |
*3年間で¥ 153396、たったの¥ 61358
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is tran... Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. 詳細を表示
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported two senior...
- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data...
The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to...
BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the...
Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease...
Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.52 | -14.7859922179 | 10.28 | 10.83 | 8.75 | 118502 | 9.54856967 | CS |
| 4 | -5.74 | -39.5862068966 | 14.5 | 14.6215 | 8.75 | 91870 | 11.31867442 | CS |
| 12 | -9.6 | -52.2875816993 | 18.36 | 20.63 | 8.75 | 88400 | 13.58957682 | CS |
| 26 | -9.94 | -53.1550802139 | 18.7 | 22.57 | 8.75 | 78426 | 14.84600666 | CS |
| 52 | -1.24 | -12.4 | 10 | 26.3789 | 5.85 | 51034 | 15.4109855 | CS |
| 156 | -4.74 | -35.1111111111 | 13.5 | 26.3789 | 4.22 | 51357 | 13.51624026 | CS |
| 260 | -4.74 | -35.1111111111 | 13.5 | 26.3789 | 4.22 | 51357 | 13.51624026 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
